Thinking Outside The Box On Rx Pricing: From Vaccines To Part D Bundling
This article was originally published in RPM Report
Executive Summary
Former FDA Deputy Commissioner suggest Vaccine-For-Children model for high value drug purchasing programs during Johns Hopkins drug pricing conference. Bundled payments in Part D is another option put on the table. Medicare head Cavanaugh explains why that option is much harder to accomplish.
You may also be interested in...
Part B Demo Could Save $2.2 Bil., CBO Says; Blocking It Would Cost Less
CMS’ proposal to test alternate payment methods for Part B drugs could save as much as $2.2 billion over 10 years, the Congressional Budget Office told Congress. However, a bill to block implementation of the program would only cost $395 million for scoring purposes.
Watchful Waiting On Drug Prices In Part D
CMS is shaking things up in Medicare Part B with a proposed demonstration project to test alternative reimbursement models for prescription drugs. But in Part D, CMS is taking more of a wait-and-see approach – at least in the annual update to the rules for bids on offering the insurance benefit.
Lilly, Anthem Singing Same Tune On Value-Based Pricing, Communication Policy
“Project Indy” offers a joint manufacturer/payor perspective on how to enable value based pricing. It also sounds like a potential proposal to CMS to volunteer for a pilot project.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: